# NAD+ 1000 mg

Client Peptide Bros · Nicotinamide adenine dinucleotide

VERIFIED ID **NP-B7RNAD-N10**

*Sample as received*

CLIENT
**Peptide Bros**

SAMPLE REFERENCE
**NPA-26-09105**

CLIENT LOT
**PB-NAD-1000-2609**

DATE RECEIVED
**10 Sep 2026**

DATE ANALYSED
**17 Sep 2026**

DATE ISSUED
**18 Sep 2026**

Scan QR to verify

HPLC PURITY (AREA %)

## 99.44%

RP-HPLC-UV 260 nm · single dominant peak

IDENTITY (ESI-MS)

## Confirmed

Theory 663.43 Da
Found 663.45 Da
Δ = 0.02 Da

NET CONTENT

## 1059 mg

Appearance: off-white cake · amber vial
Endotoxin: not requested

COLUMN / METHOD
**C18 4.6 × 250 mm, 5 µm · H2O/MeCN + 0.1% TFA**

MAIN PEAK RT
**4.86 min**

ANALYST
**A. Chen, M.Sc.**

REVIEWER
**R. Singh, Ph.D.**

LABORATORY
**Vancouver, BC**

Statement

The results above describe the sample as received under the sample reference on this certificate. They do not certify any other vial, lot, or subsequent handling. HPLC purity is chromatographic area percent and is not net peptide content. Identity is intact-mass agreement with the theoretical mass of the named sequence.

*Electronically issued. Verify at the URL encoded in the QR code. Printed copies are uncontrolled.*
*NorthPeak Analytical Ltd. does not manufacture or sell peptides.*

# Chromatogram and peak table

RP-HPLC-UV 260 nm · Sample NPA-26-09105 · NP-B7RNAD-N10




## Integrated peaks

| # | RT (min) | Area % | Assignment |
|---|---|---|---|
| 1 | 4.21 | 0.31 | Related impurity |
| **2** | **4.86** | **99.44** | **NAD+ (main peak)** |
| 3 | 5.44 | 0.36 | Related impurity |

## Method notes

Mobile phase A: water + 0.1% TFA. Mobile phase B: acetonitrile + 0.1% TFA.
Gradient: 5–65% B over 12 min, 1.0 mL/min, column 30 °C, injection 10 µL.
Purity = (main peak area / sum of integrated peak areas) × 100.
Salts, counter-ions and residual water are not quantified by UV and are not reported as HPLC impurities.
Mass confirmation by positive-mode ESI. Acceptance: observed mass within ±0.5 Da of theory for this peptide class.